<DOC>
	<DOCNO>NCT02630056</DOCNO>
	<brief_summary>The purpose study validate dosimetric parameter correlate acute hematologic toxicity ( HT ) patient rectal cancer treat neoadjuvant chemoradiotherapy .</brief_summary>
	<brief_title>Validate Dosimetric Parameters That Correlate With Acute Hematologic Toxicity ( HT ) Patients With Rectal Cancer</brief_title>
	<detailed_description>The investigator ' ongoing retrospective study investigate clinical dosimetric parameter ( dosimetry pelvic bone marrow ) relate acute hematologic toxicity patient rectal cancer treat neoadjuvant chemoradiotherapy . In order validate dosimetric limitation pelvic bone marrow decrease intensity HT , investigator want conduct study observe acute HT without assign specific intervention subject study , receive standard treatment accord multidisciplinary team 's ( MDT ) decision patient choice . Therefore , study 's type observational .</detailed_description>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<criteria>rectal cancer receive neoadjuvant chemoradiotherapy hematological system disorder</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>radiotherapy hematologic toxicity pelvic bone marrow</keyword>
</DOC>